Clinical trials: NK T-Cell Lymphoma
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or…
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT05475925
- Testing
- DR-01
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Dren Bio
Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
This is a single-arm, open, multi-center, phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection in Relapsed or refractory peripheral t-cell and NK/T-cell lymphoma.
- Trial name
- NCT03776279
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 106 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Extranodal NK/T-cell Lymphoma, Nasal Type
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal…
- Trial name
- NCT04509466
- Testing
- Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
- Where
- China
- Volunteers
- 41 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Lymphoma, Extranodal NK-T-Cell, EBV
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
- Trial name
- CITADEL (NCT01948180)
- Testing
- baltaleucel-T
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Cell Medica Ltd
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus…
- Trial name
- NCT03397706
- Testing
- VRx-3996 and valganciclovir
- Where
- 28 sites in United States, Brazil
- Volunteers
- 64 people
- Sponsor
- Viracta Therapeutics, Inc.